RemeGen Co (HKSE:09995) Float Percentage Of Total Shares Outstanding : 0.00% (As of May. 22, 2024)

View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, RemeGen Co's float shares is 0.00 Mil. RemeGen Co's total shares outstanding is 544.26 Mil. RemeGen Co's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, RemeGen Co's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, RemeGen Co's Institutional Ownership is 12.97%.

RemeGen Co Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

RemeGen Co's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	0.00	/	544.26
	=	0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RemeGen Co (HKSE:09995) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

REGMF:USA REG:Germany 688331:China

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

http://www.remegen.com

RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).

RemeGen Co (HKSE:09995) Headlines

No Headlines